/
Gastroenterology
Peptic Ulcer
16
Pipeline Programs↗
9
Active Trials↗
11
Companies Involved↗
Peptic ulcer is an emerging landscape with 16 programs across 11 companies. The most active players are Takeda, Onconic Therapeutics Inc., Shandong New Time Pharmaceutical Co., LTD. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical13
Phase 1
No programs
Approved
No programs
Analysis
Trial Status
58
clinical trials
Completed32 · 55%
Unknown status10 · 17%
Recruiting6 · 10%
Terminated4 · 7%
Not yet recruiting3 · 5%
Withdrawn3 · 5%
Clinical Trials
Trial Activity
58 trials
Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment
Recruiting·—·N/A·NCT06894992·162 enrolled
PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers
Recruiting·—·Phase 4·NCT05582174·594 enrolled
Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease
Recruiting·—·N/A·NCT07260006·80 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)